JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/55/0.1/21.11.25 Stock JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/55/0.1/21.11.25
Add to a list
To use this feature you must be a member
Log inSign up

JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/55/0.1/21.11.25 Stock

Warrant

DE000JB80DB8

Market Closed - Bid/Ask 02:32:39 2024-06-27 am EDT After market 02:38:55 pm
0.19 EUR -5.00% Intraday chart for JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/55/0.1/21.11.25 0.175 -7.89%
Current month+33.33%
1 month+17.65%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart BRISTOL-MYERS SQUIBB COMPANY
Chart JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/55/0.1/21.11.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
More news

Quotes 5-day view

Date Price Change
24-06-27 0.19 -5.00%
24-06-26 0.2 0.00%
24-06-25 0.2 -4.76%
24-06-24 0.21 +23.53%
24-06-21 0.17 +6.25%

Delayed Quote Börse Stuttgart

Last update June 27, 2024 at 02:32 am EDT

More quotes

Static data

Product typeWarrant Plain-Vanilla
Buy / SellCALL
Underlying BRISTOL-MYERS SQUIBB COMPANY
Issuer J.P. Morgan
WKN JB80DB
ISINDE000JB80DB8
Date issued 2023-12-19
Strike 55 $
Maturity 2025-11-21 (512 Days)
Parity 10 : 1
Emission price 0.49 €
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.67 €
Lowest since issue 0.14 €
Spread 0.01 €
Spread %5.26%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
-
More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Bristol-Myers Squibb Company

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.5 USD
Average target price
53.19 USD
Spread / Average Target
+25.16%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant